Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: This study aimed to assess the impact of combination antithrombotic therapy on stroke and bleeding risk compared with anticoagulation therapy only in patients with atrial fibrillation (AF).
Methods: Post hoc analysis of 4,576 patients with AF (mean ± SD age, 70.1 ± 9.1 years; men, 66.5%) enrolled in the Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS) trial were randomized to receive either subcutaneous idraparinux (2.5 mg weekly) (n = 2,283) or dose-adjusted vitamin K antagonists (VKAs) (international normalized ratio, 2.0-3.0) (n = 2,293). Of these patients, 848 (18.5%) received antiplatelet therapy (aspirin, clopidogrel, ticlopidine, etc) in addition to anticoagulation treatment (combination antithrombotic therapy).
Results: A total of 572 (15.3% per year) clinically relevant bleeding and 103 (2.6% per year) major bleeding events occurred. Patients receiving combination antithrombotic therapy had a 2.3- to 2.5-fold increased risk of clinically relevant bleeding events and major bleeding events, respectively, compared with those receiving anticoagulation therapy only. Multivariate analyses (hazard ratio, 95% CI) revealed that the risk of clinically relevant bleeding was significantly increased by age 65 to 74 years (1.44, 1.14-1.82) and ≥ 75 years (1.59, 1.24-2.04, P = .001) and by combination antithrombotic therapy (2.47, 2.07-2.96, P < .0001). The same held true for major bleeding events, with analogous figures for age 65 to 74 years (2.26, 1.08-4.71) and ≥ 75 years (4.19, 1.98-8.87, P = .0004) and for combination antithrombotic therapy (2.23, 1.49-3.34, P < .0001). Combination antithrombotic therapy was not associated with a decrease in ischemic stroke risk compared with anticoagulation therapy only (11 [1.4% per year] vs 22 [0.7% per year]; adjusted hazard ratio, 2.01; 95% CI, 0.94-4.30; P = .07).
Conclusions: Combination antithrombotic therapy increases the risk of clinically relevant bleeding and major bleeding in patients with AF and does not appear to reduce the risk of stroke.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1378/chest.10-3270 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Increased bleeding complications after nasolabial interpolation flap repair with only combined antiplatelet and anticoagulation use. A retrospective, single-center experience.
J Am Acad Dermatol
September 2025
Department of Dermatology, Hospital of the University of Pennsylvania; Philadelphia, PA. Electronic address:
A combination of tetramethylpyrazine and berberine prevents coronary microembolization in rats by regulating miR-34a-5p in platelet-derived exosomes.
J Ethnopharmacol
September 2025
National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. Electronic address:
Ethnopharmacological Relevance: Both chuanxiong rhizome and Coptis chinensis were first recorded in the Shennong's Classic of Materia Medica. Chuanxiong rhizome and Coptis chinensis are a classic herbal pair in Traditional Chinese Medicine (TCM), renowned for their effects in activating blood circulation and resolving toxicity. They are widely used to treat chest impediment and heart pain.
View Article and Find Full Text PDFIndobufen Versus Aspirin Plus Clopidogrel in Patients After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the OPTION Trial.
J Diabetes
September 2025
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.
Background: Despite increased risk of ischemic events in diabetes, the optimal anti-thrombotic strategy for secondary prevention has not been defined. We aimed to assess the efficacy and safety of optimal antiplatelet agents such as indobufen-based dual antiplatelet therapy (DAPT) in patients with diabetes after coronary stenting.
Methods: OPTION trial was a randomized, open-label, noninferiority, and multicentric study in China.
Antithrombotic strategies in adult COVID-19 patients: a systematic review and Bayesian network meta-analysis.
BMJ Open
September 2025
Jiangsu Provincial Key Laboratory of Critical Care Medicine, Nanjing, Jiangsu, China
Objectives: To systematically compare the effects of various antithrombotic strategies on prespecified outcomes including 28-day all-cause mortality (primary outcome), major thrombotic events and major bleeding events (secondary outcomes) in adult COVID-19 patients.
Design: Systematic review and Bayesian network meta-analysis (NMA).
Data Sources: PubMed, Web of Science, Embase, Cochrane Library and ClinicalTrials.
Free-Floating Thrombus in Stroke: Therapeutic Dilemmas and Case Series Analysis.
Cureus
July 2025
Department of Neurology, Ibn Rochd University Hospital, Casablanca, MAR.
Background And Aims: Free-floating thrombus (FFT) is a rare but clinically significant vascular finding, not only in ischemic stroke but also in other contexts such as routine imaging for asymptomatic patients or evaluation of other vascular diseases. It is characterized by an intraluminal thrombus adherent to the arterial wall with partial luminal occlusion and cyclic movement synchronized with the cardiac cycle. Although associated with an increased risk of embolic complications, including recurrence, no consensus exists regarding optimal management.
View Article and Find Full Text PDF